Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial

The randomized phase 3 HYPRO trial compared hypofractionated radiotherapy of 64.6 Gy in 19 fractions of 3.4 Gy versus conventionally fractionated treatment of 79 Gy in 39 fractions of 2 Gy in patients with localized prostate cancer. Quality of life was measured using the validated EORTC-QLQ-PR 25 questionnaire. Non-inferiority of hypofractionation could not be demonstrated for genitourinary and gastrointestinal quality of life, but was demonstrated for androgen-deprivation therapy-related symptoms, sexual activity and sexual function.

https://ift.tt/2RXT4CY